According to a study, immunotherapy drugs are well tolerated by patients with lung cancer who have limited physical function.

Published Date: 22 Nov 2023

Durvalumab, an immune checkpoint inhibitor medication, is safe and may improve overall survival for patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, per a new study.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot